Akatinol Memantine, 10 mg 90 pcs

Akatinol Memantine is a myorelaxant of central action.

Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA)-receptors it has modulating effect on glutamatergic system.

It regulates ion transport, blocks calcium channels, normalizes membrane potential, improves nerve impulse transmission, improves cognitive processes, memory and learning ability, and increases daily activity.

Indications

Active ingredient

Composition

Shell tablets

1 tablet.:

memantine hydrochloride 10 mg

auxiliary substances:

Lactose;

MCC;

Colloidal silica;

Talc;

Magnesium stearate coating:

methacrylic acid copolymer;

sodium lauryl sulfate;

polysorbate 80;

triacetin;

simethicone emulsion;

t talc

How to take, the dosage

Akatinol Memantine is taken orally, with meals. Dosing regimen is set individually. It is recommended to start treatment with prescription of the lowest effective dose.

In adults with dementia during the 1st week of therapy – in a dose of 5 mg/day, the 2nd week – in a dose of 10 mg/day, the 3rd week – in a dose of 15-20 mg/day. If necessary, further weekly dose increase by 10 mg to reach a daily dose of 30 mg.

The optimal dose is reached gradually, increasing the dose each week.

Interaction

Concomitant use with L-dopa drugs, dopamine agonists, anticholinergic agents may increase the effect of the latter.

Concomitant use with barbiturates, neuroleptics may decrease their effect.

When used concomitantly it can change (increase or decrease) the effect of dantrolene or baclofen, so the doses of the drugs should be adjusted individually.

Concomitant administration with amantadine, ketamine, and dexamethorphan should be avoided.

Possible increase in plasma levels of cimetidine, procainamide, quinidine, quinine and nicotine when concomitantly taken with memantine.

Hydrochlorothiazide levels may decrease when concomitantly taken with memantine.

Special Instructions

Patients with moderate to severe dementia with Alzheimer’s disease usually have impaired ability to drive vehicles and operate complex machinery.

In addition, memantine may cause changes in reaction speed, so patients treated as outpatients should use extra caution when driving or operating machinery.

Contraindications

Side effects

The adverse reactions are classified according to clinical manifestations (according to the involvement of certain organ systems) and frequency of occurrence: Very common – ≥1/10; common – ≥1/100-

In the body as a whole – general adverse reactions

Frequently

Headache

Rarely

Fatigue

Infections

Rarely

Fungal infections

Mental disorders

Often

Sleepiness

Rarely

Rarely

Consciousness confusion

Hallucinations

Frequency not established

Psychotic reactions

Cardiovascular disturbances

Rarely Hypertension

Rarely Venous thrombosis/thromboembolism

Gastrointestinal disorders

Often Constipation

RarelyNausea,Vomiting

Frequency not determined

Pancreatitis

Central and peripheral nervous system disorders

Often Dizziness

Rarely Impaired gait

p> Very rare Seizures

1 Hallucinations have been observed mainly in patients with Alzheimer’s disease at the stage of severe dementia.

2 There have been anecdotal reports of these adverse reactions when the drug is used in clinical practice (data obtained after the drug was commercially available).

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Pregnancy use

It is contraindicated in pregnancy.

Breastfeeding should be stopped during treatment.

Similarities